Social anxiety disorder in review: Two decades of progress

International Journal of Neuropsychopharmacology

Volumn 4, Issue 3, 2001, Pages 279-298

  Hidalgo, Rosario B ^a   Barnett, Stewart D ^a   Davidson, Jonathan R T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anxiety; Anxiety treatment; Diagnosis of anxiety; Neurobiology of anxiety; Social phobia

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROFAROMINE; BROMAZEPAM; BUSPIRONE; CLONAZEPAM; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; ONDANSETRON; PAROXETINE; PHENELZINE; PREGABALIN; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANXIETY NEUROSIS; AWARENESS; CALCULATION; CLINICAL TRIAL; COMORBIDITY; COST OF ILLNESS; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; ETHOLOGY; FEMALE; GENDER; GENERAL PRACTITIONER; HEALTH CARE COST; HISTORY OF MEDICINE; HUMAN; INCIDENCE; MALE; NEUROBIOLOGY; NEUROENDOCRINOLOGY; NEUROTRANSMISSION; ONSET AGE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; PSYCHOTRAUMA; RELAPSE; REVIEW; SEX DIFFERENCE; SOCIAL PHOBIA;

HUMANS; NEUROTRANSMITTER AGENTS; PHOBIC DISORDERS;

EID: 0035698972     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145701002504     Document Type: Review

References (139)

1. Paroxetine in social anxiety disorder: A randomized placebo-controlled study
2. Venlafaxine in social phobia: A study in selective serotonin reuptake inhibitor nonresponders
3. Prevalence, comorbidity, disability and service utitisation. Overview of the Australian National Mental Health Survey
4. The role of perceived parental rearing practices in the aetiology of phobic disorders: A controlled study
5. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study
6. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety
7. The neurobiology of social phobia
8. 3 antagonist, ondansetron, in social phobia
9. Autonomic failure, depression and anxiety in Parkinson's disease
10. fMRI reveals amygdala activation to human faces in social phobics
11. Social phobia: Diagnosis, and epidemiology, neurobiology and pharmacology, comorbidity and treatment
12. 2 challenge test in patients with social phobia
13. Discontinuation of clonazepam in the treatment of social phobia
14. Psychometric properties of the social phobia inventory (SPIN): A new self-rating scale
15. Flumazenil challenge in social phobia
16. The diagnostic utility of lactate sensitivity in panic disorder
17. Pharmacotherapy of social anxiety disorder
18. Magnetic resonance spectroscopy in social phobia: Preliminary findings
19. Treatment of social phobia with clonazepam and placebo
20. The boundary of social phobia. Exploring the threshold
21. The epidemiology of social phobia: Findings from the Duke Epidemiological Catchment Area Study
22. The Zurich study. XX. Social phobia and agoraphobia
23. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin
24. Imipramine in the treatment of social phobia: A double-blind placebo-controlled study
25. Treatment of social phobia with bupropion
26. Personality traits in social phobia. Comparison with healthy controls
27. Social phobia: The clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study
28. Epidemiology of anxiety disorders in Florence
29. A direct interview family study of social phobia
30. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study
31. Ventilatory physiology of patients with panic disorder
32. Treatment of social phobia with atenolol
33. High-dose carbon dioxide challenge test in anxiety disorder patients
34. The economic burden of anxiety disorders in the 1990s
35. Specific issues in the cognitive-behavioral treatment of social phobia
36. DSM-III-R subtypes of social phobia: Comparison of generalized social phobics and public speaking phobics
37. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome
38. Validity on the distinction between generalized social phobia and avoidant personality disorder
39. Serotonergic function in social phobia: Comparison to normal control and obsessive-compulsive disorder subjects
40. Avoidant personality disorder and the generalized subtype of social phobia
41. Hyperventilation and anxiety in panic disorder, social phobia, GAD and normal controls
42. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study
43. Beneficial effect of nadolol on anxiety-induced disturbances of performance in musicians: A comparison with diazepam and placebo
44. Plasma and CSF HVA levels in panic patients with comorbid social phobia
45. Abnormal peripheral benzodiazepine receptor density associated with generalized social phobia
46. Role of GABA in memory and anxiety
47. Sertraline for social phobia: A double-blind, placebo-controlled crossover study
48. Venlafaxine in social phobia
49. The genetic epidemiology of phobias in women. The interrelationship of agoraphobia, social phobia, situational phobia, and simple phobia
50. The impact of psychiatric disorders on work loss days
51. Social phobia subtypes in the National Comorbidity Survey
52. Past-year use of outpatient services for psychiatric problems in the National Comorbidity Survey
53. CSF dopamine levels correlate with extraversion in depressed patients
54. MAOIs: Impact on social behavior
55. Specificity of lactate infusions in social phobia versus panic disorders
56. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison
57. Brofaromine for social phobia: A multicenter, placebo-controlled, double-blind study
58. Effects of negative life experiences on phobia onset
59. Neural correlates of anxiety provocation in social phobia
60. Generalized social phobia: Reliability and validity
61. Brief standard self-rating for phobic patients
62. Psychosocial treatments for social phobia
63. A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls
64. School avoidance and social phobia triggered by haloperidol in patients with Tourette's disorder
65. Conditioning and ethological models of anxiety disorders: Stress-in dynamic-context anxiety models
66. Stage fright in musicians: A model illustrating the effect of beta blockers
67. Short stature, growth hormone deficiency, and social anxiety
68. Moclobemide in social phobia: A controlled dose-response trial
69. Brain mechanisms of social anxiety disorder
70. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepinereceptor sensitivity in panic disorder
71. Treatment of social phobia with gabapentin: A placebocontrolled study
72. Epinephrine infusions in patients with social phobia
73. Reported parental characteristics of agoraphobics an social phobics
74. Carbon dioxide/oxygen challenge test in panic disorder
75. Magnetic resonance imaging in social phobia
76. Levels of urinary free cortisol in social phobia
77. Gabapentin decreases monoamine release without affecting acetylcholine release in the brain
78. Subcortical correlates of differential classical conditioning of aversive emotional reactions in social phobia
79. Placebo-controlled trial of moclobemide in social phobia
80. Comorbidity and morbidity in an epidemiologic sample
81. Low dopamine D receptor binding potential in social phobia
82. Social phobia
83. Buspirone in social phobia
84. Imipramine in the treatment of social phobia
85. Low dose selegiline (L-Deprenyl) in social phobia
86. Responders and non-responders to drug treatment in social phobia: Differences at baseline and prediction of response
87. Evidence for social phobia and other psychiatric disorders in adults who were growth hormone deficient during childhood
88. Autonomic responsivity in generalized social phobia
89. A direct-interview family study of generalized social phobia
90. Paroxetine in the treatment of generalized social phobia: Open-label treatment and double-blind placebo-controlled discontinuation
91. 3H]paroxetine binding to platelets of patients with social phobia: Comparison to patients with panic disorder and healthy volunteers
92. Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study
93. A brain single photon-emission computed tomography (SPECT) study of generalized social phobia
94. Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial
95. Social phobia in the primary care medial setting
96. Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders. Comparison of patients with panic disorder and social phobia and normal control subjects
97. Childhood physical and sexual abuse in patients with anxiety disorders and in a community sample
98. Setting diagnostic thresholds for social phobia: Considerations from a community survey of social anxiety
99. A 2-year follow-up of social phobia. Status after a brief medication trial
100. Neurobiology of social phobia
101. Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia
102. The hypothalamic-pituitary-thyroid axis in social phobia
103. Effects of thyrotropin-releasing hormone on blood pressure and heart rate in phobic and panic patients: A pilot study
104. Growth hormone response to intravenous clonidine in social phobia: Comparison to patients with panic disorder and healthy volunteers
105. Lactic acid response to caffeine in panic disorder: Comparison with social phobics and normal controls
106. Mechanisms of action of gabapentin
107. A summary of mechanistic hypotheses of gabapentin pharmacology
108. Meta-analysis of cognitive-behavioral treatments for social phobia
109. Dopamine reuptake site densities in patients with social phobia
110. A repeat proton magnetic resonance spectroscopy study in social phobia
111. Two-year follow-up of social phobias treated with Social Effectiveness Therapy
112. Social phobia: A comparison of behavior therapy and atenolol
113. Anxiety and growth disturbance: Is there a connection? A review of biological studies in social phobia
114. Normal urinary free cortisol and postdexamethasone cortisol in social phobia: Comparison to normal volunteers
115. Nefazodone in social phobia
116. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia
117. Sertraline treatment of social phobia: A 20-week, double-blind, placebo-controlled study
118. Psychopharmacological treatment of social phobia: Clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor
119. Psychopharmacological treatment of social phobia: A double blind placebo controlled study with fluvoxamine
120. Clinical effects of buspirone in social phobia: A double-blind placebo-controlled study
121. Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls
122. Double-blind placebo controlled trial with bromazepam in social phobia
123. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine
124. The long-term treatment of social phobia with moclobemide
125. Identification of cases of anxiety disorders and affective disorders in the community according to the ICD-10 and DSM-III-R using the composite international diagnostic interview (CIDI)
126. Social phobia in general health care. An unrecognised undertreated disabling disorder
127. The nature of social anxiety disorder
128. The impact of social phobia on quality of life
129. Prevalence of mental disorders and psychosocial impairments in adolescents and young adults
130. Nefazodone for social phobia: A clinical case series